Key points are not available for this paper at this time.
The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Hurwitz et al. (Wed,) studied this question.